UNITED ~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549~~STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 ORor 15d-1616UNDER ~~UNDER~~ THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~November~~December ~~30,~~ 2020

Commission File Number: 333-229744

EMERALD HEALTH THERAPEUTICS, INC. (Translation of ~~Registrant’~~registrant's name into English)

210 - 800 West Pender ~~StreetVancouver~~Street Vancouver, British Columbia V6C 1J8 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

~~[ X ]~~ Form 20-F ~~[ ]~~ ☐ Form 40-F ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ~~[ ]~~☐

~~Indicate~~Note: byRegulation ~~check~~S-T ~~mark~~Rule if101(b)(1) only permits the ~~registrant~~submission isin ~~submitting~~paper ~~the~~of a Form 6-K inif ~~paper~~submitted assolely ~~permitted~~to byprovide ~~Regulation~~an ~~S-T~~attached ~~Rule~~annual ~~101(b)(7):~~report ~~[ ]~~to security holders.

~~INCORPORATION~~Indicate BYby ~~REFERENCE~~check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

~~Exhibits~~Note: ~~99.1~~Regulation ~~and~~S-T ~~99.2~~Rule to101(b)(7) ~~this~~only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of ~~Emerald~~the ~~Health~~jurisdiction ~~Therapeutics~~in which the registrant is incorporated, ~~Inc.~~domiciled or legally organized (the ~~“Company”~~registrant's "home country"), ~~are~~or ~~hereby~~under ~~incorporated~~the byrules ~~reference~~of the home country exchange on which the registrant's securities are traded, as ~~exhibits~~long toas the ~~Registration~~report ~~Statement~~or onother ~~Form~~document ~~F-10~~is ~~(File~~not ~~No.~~a ~~333-229744)~~press ofrelease, is not required to be and has not been distributed to the ~~Company~~registrant's security holders, asand, ~~amended~~if discussing a material event, has already been the subject of a Form 6-K submission or ~~supplemented~~other Commission filing on EDGAR.

~~EXHIBITS~~EXHIBIT INDEX

99.1		Condensed Consolidated Interim Financial Statements for the Three and Nine Months Ended September 30, 2020 and 2019
Exhibit		Description
99.2		Management's Discussion and Analysis for the Three and Nine Months Ended September 30, 2020
99.1		News Release dated December 1, 2020
99.3		Certification of Interim Filings - CEO
99.4		Certification of Interim Filings - CFO

~~SIGNATURES~~- 2 -

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Emerald Health Therapeutics, Inc.(Registrant)
Date: November 30, 2020	By:	/s/ Dr. Avtar Dhillon
Date: December 1, 2020	By	/s/ Dr. Avtar Dhillon
		Name: Dr. Avtar Dhillon
		Avtar Dhillon
		Title: Executive Chairman
		Executive Chairman

- 3 -

Filing Compare · Emerald Health Therapeutics Inc.